Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which ...

In the latest close session, C3.ai, Inc. (AI) was down 1.06% at $24.22. The stock trailed the S&P 500, which registered a daily loss of 0.13%. Elsewhere, the Dow saw a downswing of 0.39%, while the ...